Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator

Hypertension

Volumn 27, Issue 4, 1996, Pages 1009-1017

  Brasier, Allan R ^a,b   Li, Junyi ^a   Wimbish, Kenneth A ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

acute phase reaction; angiotensinogen; nuclear factor kappa B; renin angiotensin system

Indexed keywords

ANGIOTENSINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANTIBODY SPECIFICITY; CONFERENCE PAPER; DNA BINDING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPORTER GENE;

EID: 0029863473     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.4.1009     Document Type: Conference Paper

References (69)

1. Ron D, Brasier AR, Wright KA, Tate JE, Habener JF. An inducible 50-kilodalton NF kappa B-like protein and a constitutive protein both bind the acute-phase response element of the angiotensinogen gene. Mol Cell Biol. 1990;10:1023-1032.
2. Brasier AR, Ron D, Tate JE, Habener JF. A family of constitutive C/EBP-like DNA binding proteins attenuate the IL-1 alpha induced, NF kappa B mediated trans-activation of the angiotensinogen gene acute-phase response element. EMBO J. 1990;9: 3933-3944.
3. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest. 1986;78:31-39.
4. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79:1-6.
5. Cassio D, Weiss MC, Ott M-O, Sala-Trepat JM, Fries J, Erdos T. Expression of the albumin gene in rat hepatoma cells and their dedifferentiated variants. Cell. 1981;27:351-358.
6. Coezy E, Bouhnik J, Clauser E, Pinot F, Philippe M, Menard J, Corvol P. Effects of glucocorticoids and antiglucocorticoids on angiotensinogen production by hepatoma cells in culture. In Vitro. 1984;20:528-534.
7. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977;57:313-370.
8. Reid IA, Morris BJ, Ganong WG. The renin-angiotensin system. Annu Rev Physiol. 1978;40:377-410.
9. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark AJ. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med. 1994;330:1629-1633.
10. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
11. Watt GCM, Harrap SB, Foy CJW, Holton DW, Edwards HV, Davidson HR, Connor JM, Lever AF, Fraser R. Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four corners approach to the identification of genetic determinants of blood pressure. J Hypertens. 1992;10:473-482.
12. Walker WG, Whelton PK, Saito H, Russel RP, Hermann J. Relation between blood pressure and renin, renin substrate. Ang II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension. 1979;1:287-291.
13. Brasier AR, Philippe J, Campbell DJ, Habener JF. Novel expression of the angiotensinogen gene in a rat pancreatic islet cell line: transcriptional regulation by glucocorticoids. J Biol Chem. 1986;261:16148-16154.
14. Brasier AR, Ron D, Tate JE, Habener JF. Synergistic enhansons located within an acute phase responsive enhancer modulate glucocorticoid induction of angiotensinogen gene transcription. Mol Endocrinol. 1990;4:1921-1933.
15. Ben-Ari ET, Lynch KR, Garrison JC. Glucocorticoids induce the accumulation of novel angiotensinogen gene transcripts. J Biol Chem. 1989;264:13074-13079.
16. Sernia C, Clements JA, Funder JW. Regulation of liver angiotensinogen mRNA by glucocorticoids and thyroxine. Mol Cell Endocrinol. 1989;61:147-156.
17. Gordon MS, Chin WW, Shupnik MA. Regulation of angiotensinogen gene expression by estrogen. J Hypertens. 1992;10:361-366.
18. Hong-Brown LQ, Deschepper CF. Effects of thyroid hormones on angiotensinogen gene expression in rat liver, brain, and cultured cells. Endocrinology: 1992;130:1231-1237.
19. Kimura S, Iwao H, Fukui K, Abe Y, Tanaka S. Effect of thyroid hormone on angiotensinogen and renin mRNA levels in rat. Jpn J Pharmacol. 1990;52:281 -285.
20. Eggena P, Zhu JH, Clegg K, Barren JD. Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension. 1993;22:496-501.
21. Hilgenfeldt U, Schwind S, Angiotensin II is the mediator of the increase in hepatic angiotensinogen synthesis after bilateral nephrectomy. Am J Physiol. 1993;265:E414-E418.
22. Schmid RM, Perkins ND, Duckett CS, Andrews PC, Nabel GJ. Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. Nature. 1991;352:733-736.
23. Nakamura A, Iwao H, Fukui K, Kimura S, Tamaki T, Nakanishi S, Abe Y. Regulation of liver angiotensinogen and kidney renin mRNA levels by angiotensin II. Am J Physiol. 1990;258:E1-E6.
24. Saye JA, Cassis LA, Sturgill TW, Lynch KR, Peach MJ. Angiotensinogen gene expression in mouse 3T3-L1 cells. Am J Physiol. 1989;256:C448-C451.
25. Ron D, Brasier AR, McGehee RE Jr, Habener JF. Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). J Clin Invest. 1992;89:223-233.
26. Brasier AR, Tate JE, Ron D, Habener JF. Multiple cis-acting DNA regulatory elements mediate hepatic angiotensinogen gene expression. Mol Endocrinol. 1989;3:1022-1034.
27. McGehee RE Jr, Ron D, Brasier AR, Habener JF. Differentiation-specific element: a cis-acting developmental switch required for the sustained transcriptional expression of the angiotensinogen gene during hormonal-induced differentiation of 3T3-L1 fibroblasts to adipocytes. Mol Endocrinol. 1993;7:551-560.
28. Ron D, Brasier AR, Habener JF. Angiotensinogen gene-inducible enhancer-binding protein 1, a member of a new family of large nuclear proteins that recognize nuclear factor kappa B-binding sites through a zinc finger motif. Mol Cell Biol. 1991;11:2887-2895.
29. Ron D, Brasier AR, Wright KA, Habener JF. The permissive role of glucocorticoids on interleukin-1 stimulation of angiotensinogen gene transcription is mediated by an interaction between inducible enhancers. Mol Cell Biol. 1990;10:4389-4395.
30. Ron D, Brasier AR, Habener JF. Transcriptional regulation of hepatic angiotensinogen gene expression by the acute-phase response. Mol Cell Endocrinol. 1990;74:C97-C104.
31. Baeuerle PA. The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta. 1991;1072:63-80.
32. Urban MB, Baeuerle PA. The 65-kD subunit of NF-kappa B is a receptor for I kappa B and a modulator of DNA-binding specificity. Genes Dev. 1990;4:1975-1984.
33. Baeuerle PA, Baltimore D. A 65-kDa subunit of active NF-kappaB is required for inhibition of NF-κB by IκB. Genes Dev. 1989;3: 1689-1698.
34. Beg AA, Baldwin AS Jr. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev. 1993;7:2064-2070.
35. Kunsch C, Ruben SM, Rosen CA. Selection of optimal κB/Rel DNA-binding motifs: interaction of both subunits of NF-κB with DNA is required for transcriptional activation. Mol Cell Biol. 1992;12:4412-4421.
36. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle PA, Blasi F. A novel complex between the p65 subunit of NF-κB and c-Rel hinds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J. 1992;11:205-213.
37. Ryseck R-P, Bull P, Takamiya M, Bours V, Siebenlist U, Dobrzanski P, Bravo R. RelB, a new Rel family transcription activator that can interact with p50-NF-κB. Mol Cell Biol. 1992;12:674-684.
38. Urban MB, Schreck R, Baeuerle PA. NF-kappa B contacts DNA by a heterodimer of the p50 and p65 suhunit. EMBO J. 1991;10: 1817-1825.
39. Brasier AR, Ron D. Luciferase reporter gene assay in mammalian cells. Methods Enzymol. 1992;216:386-397.
40. Brasier AR, Tate JE, Habener JF. Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. Bio-techniques. 1989;7:1116-1122.
41. Sadowski I, Ptashne M. A vector for expressing GAL4 (1-147) in mammalian cells. Nucleic Acids Res. 1989;17:7539.
42. Kieran M, Blank V, Logeat F, Vandekerckhove J, Lottspeich F, Le Bail O, Urban MB, Kourilsky P, Baeuerle PA, Israel A. The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell. 1990;62:1007-1018.
43. Perkins ND, Schmid RM, Duckett CS, Leung K, Rice NR, Nabel GJ. Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci USA. 1992;89:1529-1533.
44. Schmitz ML, Baeuerle PA. The p65 subunit is responsible for the strong transcription activating potential of NF-κB. EMBO J. 1991;12:3805-3817.
45. Liu F, Green MR. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell. 1990;61:1217-1224.
46. Lin Y-S, Carey MF, Ptashne M, Green MR. Gal4 derivatives function alone and synergistically with mammalian activators in vitro. Cell. 1988;54:659-664.
47. Blank V, Kourilsky P, Israel A. NF-kappa B and related proteins: Ret/dorsal homologies meet ankyrin-like repeats. Trends Biochem Sci. 1992;17:135-141.
48. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell. 1994;78:773-785.
49. Zhang Q, DiDonato JA, Karin M, McKeithan TW. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-κB proteins. Mol Cell Biol. 1994;14:3915-3926.
50. Kerr LD, Duckett CS, Wamsley P, Zhang O, Chiao P, Nabel G, McKeithan TW, Baeuerle PA, Verma IM. The proto-oncogene bcl-3 encodes an I kappa B protein. Genes Dev. 1992;6:2352-2363.
51. Tewari M, Dobrzanski P, Mohn KL, Cressman DW, Hsu J-C, Bravo R, Taub R. Rapid induction in regenerating liver of RL/IF-1 (an IκB that inhibits NF-κB, RelB-p50, and C-Rel-p50) and PHF, a novel κB site-hinding complex. Mol Cell Biol. 1992;12:2898-2908.
52. Hatada EN, Naumann M, Scheidereit C. Common structural constituents confer IκB activity to NF-κB p105 and IκB/MAD-3. EMBO J. 1993;12:2781-2788.
53. Naumann M, Scheidereit C. Activation of NF-κB in vivo is regulated by multiple phosphorylations. EMBO J. 1994;13:4597-4607.
54. Ruben SM, Narayanan R, Klement JF, Chen CH, Rosen CA. Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative. Mol Cell Biol. 1992;12:444-454.
55. Ruben SM, Dillon PJ, Schreck R, Henkel T, Chen CH, Maher M, Baeuerle PA, Rosen CA. Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science. 1991;254:11. Letter.
56. 2+ dependence. and differential half-site recognition. J Biol Chem. 1991;266: 252-260.
57. Meichle A, Schutze S, Hensel G, Bruming D, Kronke M, Protein kinase C-independent activation of NF-κB by TNF. J Biol Chem. 1990;265:8339-8343.
58. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M. Functional dichotomy of neutral and acidic sphingomyelinases in TNF signalling. Cell. 1994;78:1005-1015.
59. Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kranke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-indueed 'acidic' sphingomyelin breakdown. Cell. 1992;71:765-776.
60. Mellits KH, Hay RT, Goodbourn S. Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. Nucleic Adds Res. 1993;21:5059-5066.
61. Ghosh S, Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature. 1990;344:678-682.
62. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Bacuerle PA. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature. 1993;365: 182-185.
63. Michie HR, Manogue KR, Spriggs DR, Revhaug A. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-1486.
64. Campbell DJ, Habenar JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridation in situ. Endocrinology. 1987;121:1616-1626.
65. Cassis LA, Saye J, Peach MJ. Localization and regulation of rat angiotensinogen messenger RNA. Hypertension. 1988;11:591-596.
66. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-1321.
67. Green A, Dobias SB, Walters DJA, Brasier AR. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology. 1994;134:2581-2588.
68. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J. 1993;70:141-143.
69. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, LeJemtel TP. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation. 1994;90:12-16.